NEW YORK, March 18, 2023 /PRNewswire/ — Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the remedy of palmar hyperhidrosis making use of its patented microchannel technologies™. DTX-024 is a very purified and clinically tested injectable neuromodulator derived from neurotoxins made by Clostridium botulinum.
Aquavit Logo (PRNewsfoto/Aquavit Pharmaceuticals, Inc.)
Alongside Aquavit’s biosimilar plan for its botulinum toxin, this will be the initially in the planet, indicated for palmar hyperhidrosis, authorized by FDA.
Aquavit has been investing in proprietary delivery technologies and connected intellectual house for botulinum toxin. This is a strategic move that puts them ahead of the curve in the rapid-increasing multi-billion-dollar botulinum toxin marketplace.
To proficiently execute the approach, Aquavit has lately bolstered its executive group with seasoned veterans from the market and the academia.
Dr. David Crean, PhD, MBA has been named Chief Monetary Officer of Aquavit Holdings. He has purchase- and sell-side knowledge in mergers & acquisitions (M&A), partnering and investments inside the life sciences and healthcare sectors functioning inside strategic biopharmaceutical organizations, private equity, investment banking and venture capital. He commenced his profession inside biopharmaceutical organizations additional than 30 years ago, most notably at Allergan, an Abbvie Corporation, exactly where he lead deal execution for each technologies, item, and organization acquisitions and divestitures across a broad variety of therapeutic locations and small business units such as injectable and topical healthcare aesthetics, dermatology, neurology, and ophthalmology. He serves on a number of boards such as each public and private organizations and has been awarded a lot of recognitions such as San Diego’s 500 Most Influential individuals for the previous 4 years (2019 -2022), 2020 Best Believed Leaders by Axial, M&A Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.
Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Healthcare Officer. He is a educated neurosurgeon and neuroscientist who brings a wealth of practical experience and understanding to scientific developments, drug improvement and approval, and new drug discovery. He holds his degrees from University of Oxford and Harvard Healthcare College and at the moment holds an academic position at Columbia Healthcare College.
With Aquavit’s confirmed track record of establishing and launching worldwide brands, such as AQUAGOLD®, the organization has demonstrated their capacity to effectively bring revolutionary merchandise to marketplace. With their deep understanding of botulinum toxin and comprehensive network of physicians, Aquavit is nicely-positioned to make a important influence in the market.
“The neurotoxin marketplace is expanding quickly, with growing demand for revolutionary merchandise and customized remedy plans. There is at the moment no FDA approval for palmar hyperhidrosis and by way of our novel route of administration we will be in a position to provide new options to meet the evolving desires of individuals in pathologies that are particularly debilitating. The provision of access for this population is a step in the appropriate path towards enhancing their overall health and nicely-getting. ” Churl-Su Kwon, CMO Aquavit.
Aquavit is an revolutionary healthcare organization that offers a extensive variety of proprietary pharmaceutical, biotech and healthcare device technologies. Aquavit focuses on customized medicine to strengthen patients’ overall health, maximize the efficiency of our healthcare neighborhood, and help the pharmacoeconomics of payers.
View original content material to download multimedia:https://www.prnewswire.com/news-releases/aquavit-files-further-ind-for-dtx-024-a-new-botulinum-toxin-with-microchannel-technologies-for-palmar-hyperhidrosis-301775589.html
Supply Aquavit Holdings